Key result
Low-molecular-weight heparins demonstrate polypharmacological actions, including modulation of TFPI and inhibition of matrix-degrading enzymes, expanding their clinical utility in cancer and thrombosis.
Why the study?
Do low-molecular-weight heparins improve survival and reduce tumor growth/metastasis compared to unfractionated heparin in cancer patients with thrombosis?
Do low-molecular-weight heparins improve survival and reduce tumor growth/metastasis compared to unfractionated heparin in cancer patients with thrombosis?
LMWHs offer expanded clinical utility beyond anticoagulation in cancer patients by modulating angiogenesis, tumor growth, and metastasis through TFPI release and enzyme inhibition.
No takes yet. Share an insight, caveat, or question.
LMWHs may support expanded use in cancer-associated thrombosis; leaves open survival benefit versus unfractionated heparin.
Shaker A. Mousa (2004) conducted a review in Thrombosis and cancer. Low-molecular-weight heparins (LMWHs) vs. Unfractionated heparin (UFH) was evaluated. Low-molecular-weight heparins demonstrate polypharmacological actions, including modulation of TFPI and inhibition of matrix-degrading enzymes, expanding their clinical utility in cancer and thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: